» Articles » PMID: 36643072

SEMIPARAMETRIC DOSE FINDING METHODS FOR PARTIALLY ORDERED DRUG COMBINATIONS

Overview
Journal Stat Sin
Date 2023 Jan 16
PMID 36643072
Authors
Affiliations
Soon will be listed here.
Abstract

We investigate a statistical framework for Phase I clinical trials that test the safety of two or more agents in combination. For such studies, the traditional assumption of a simple monotonic relation between dose and the probability of an adverse event no longer holds. Nonetheless, the dose toxicity (adverse event) relationship will obey an assumption of partial ordering in that there will be pairs of combinations for which the ordering of the toxicity probabilities is known. Some authors have considered how to best estimate the maximum tolerated dose (a dose providing a rate of toxicity as close as possible to some target rate) in this setting. A related, and equally interesting, problem is to partition the 2-dimensional dose space into two sub-regions: doses with probabilities of toxicity lower and greater than the target. We carry out a detailed investigation of this problem. The theoretical framework for this is the recently presented semiparametric dose finding method. This results in a number of proposals one of which can be viewed as an extension of the Product of Independent beta Priors Escalation method (PIPE). We derive useful asymptotic properties which also apply to the PIPE method when seen as a special case of the more general method given here. Simulation studies provide added confidence concerning the good behaviour of the operating characteristics.

Citing Articles

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels.

Tighiouart M, Rogatko A Entropy (Basel). 2024; 26(8).

PMID: 39202157 PMC: 11353494. DOI: 10.3390/e26080687.


Local continual reassessment methods for dose finding and optimization in drug-combination trials.

Zhang J, Yan F, Wages N, Lin R Stat Methods Med Res. 2023; 32(10):2049-2063.

PMID: 37593951 PMC: 10563380. DOI: 10.1177/09622802231192955.


CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.

Hatayama T, Yasui S Pharm Stat. 2022; 21(6):1324-1341.

PMID: 35833753 PMC: 9796866. DOI: 10.1002/pst.2247.


A nonparametric Bayesian method for dose finding in drug combinations cancer trials.

Razaee Z, Cook-Wiens G, Tighiouart M Stat Med. 2022; 41(6):1059-1080.

PMID: 35075652 PMC: 8881404. DOI: 10.1002/sim.9316.


Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.

Yin G, Yang Z Contemp Clin Trials Commun. 2020; 19:100650.

PMID: 32875142 PMC: 7451759. DOI: 10.1016/j.conctc.2020.100650.


References
1.
Ji Y, Liu P, Li Y, Bekele B . A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010; 7(6):653-63. PMC: 5038924. DOI: 10.1177/1740774510382799. View

2.
Iasonos A, OQuigley J . Dose expansion cohorts in Phase I trials. Stat Biopharm Res. 2016; 8(2):161-170. PMC: 4976787. DOI: 10.1080/19466315.2015.1135185. View

3.
Malinovsky Y, Rinott Y . Best Invariant and Minimax Estimation of Quantiles in Finite Populations. J Stat Plan Inference. 2011; 141(8):2633-2644. PMC: 3105907. DOI: 10.1016/j.jspi.2011.02.016. View

4.
Wang K, Ivanova A . Two-dimensional dose finding in discrete dose space. Biometrics. 2005; 61(1):217-22. DOI: 10.1111/j.0006-341X.2005.030540.x. View

5.
Braun T, Wang S . A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics. 2009; 66(3):805-12. PMC: 2889231. DOI: 10.1111/j.1541-0420.2009.01363.x. View